Technical Analysis for AMPE - Ampio Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 0.57 -5.96% -0.04
AMPE closed down 5.96 percent on Friday, March 22, 2019, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
6 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical AMPE trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 50 DMA Bearish 0.00%
Mar 22 New Downtrend Bearish 0.00%
Mar 22 Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Mar 22 Bollinger Band Squeeze Range Contraction 0.00%
Mar 22 BB Squeeze + Lower Band Touch Range Contraction 0.00%
Mar 22 Below Lower BB Weakness 0.00%
Mar 22 Down 3 Days in a Row Weakness 0.00%
Mar 22 Down 4 Days in a Row Weakness 0.00%
Mar 22 Down 5 Days in a Row Weakness 0.00%
Mar 22 Lower Bollinger Band Touch Weakness 0.00%

Older signals for AMPE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction. Its products include Ampion, a non-steroidal anti-inflammatory biologic to treat inflammatory conditions and autoimmune diseases; Optina, an orally administered danazol for the treatment of diabetic macular edema; Vasaloc for the treatment of diabetic nephropathy; and Zertane, an oral drug for treating male sexual dysfunction to premature ejaculation, which is under Phase III clinical trial. The company is also developing a handheld oxidation-reduction potential diagnostic device for use at home or in healthcare facilities that will measure the oxidants/antioxidant balances in human blood and plasma; and methylphenidate derivatives for cancer, which are in pre-clinical development. Ampio Pharmaceuticals, Inc. is headquartered in Greenwood Village, Colorado.
Health Biopharmaceutical Cancer Life Sciences Diabetes Autoimmune Diseases Healthcare Facilities Diagnostic Products Kidney Diseases Diabetic Nephropathy Macular Edema Kidney Disease Metabolic Disorders Diabetic Macular Edema Diabetic Retinopathy Eye Diseases Sexual Dysfunction
Is AMPE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Feb 25 Research Report Identifies Wolverine World Wide, Viking Therapeutics, Ampio Pharmaceuticals, ArcelorMittal, Delphi Technologies, and Unit with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Feb 6 Ampio Updates Status of Pivotal Clinical Trial of Ampion to be Carried Out Under a SPA
Dec 13 FDA requires additional study of Ampio Pharma's Ampion to support marketing application; shares down 11% premarket
Dec 13 Ampio Updates Regulatory Status for Ampion
Nov 26 U.S. regulatory decision approaches for Ampio Pharma's Ampion
Nov 26 Ampio Updates Regulatory and Publication status for Ampion™
Nov 8 88 Biggest Movers From Yesterday
Nov 7 3 Health Care Stocks Rallying After US Midterms
Nov 7 Ampio Updates Regulatory and Clinical Status for Ampion™
Oct 30 Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Ampio Pharmaceuticals, Inc. (AMPE) and Encourages AMPE Investors to Contact the Firm
See more AMPE news...
Indicators
Indicator Value
52 Week High 3.89
52 Week Low 0.351
Average Volume 563,835
200-Day Moving Average 0.9354
50-Day Moving Average 0.5846
20-Day Moving Average 0.6381
10-Day Moving Average 0.6306
Average True Range 0.0455
ADX 37.81
+DI 17.7126
-DI 20.0973
Chandelier Exit (Long, 3 ATRs ) 0.6035
Chandelier Exit (Short, 3 ATRs ) 0.6915
Upper Bollinger Band 0.6934
Lower Bollinger Band 0.5828
Percent B (%b) -0.12
BandWidth 17.332707
MACD Line 0.005
MACD Signal Line 0.0163
MACD Histogram -0.0113
Fundamentals Value
Market Cap 38.89 Million
Num Shares 68.2 Million
EPS -0.21
Price-to-Earnings (P/E) Ratio -2.71
Price-to-Sales 0.00
Price-to-Book 19.82
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.65
Resistance 3 (R3) 0.66 0.63 0.64
Resistance 2 (R2) 0.63 0.61 0.63 0.63
Resistance 1 (R1) 0.60 0.60 0.59 0.60 0.63
Pivot Point 0.58 0.58 0.57 0.58 0.58
Support 1 (S1) 0.55 0.56 0.54 0.54 0.51
Support 2 (S2) 0.52 0.54 0.52 0.51
Support 3 (S3) 0.49 0.52 0.50
Support 4 (S4) 0.49